Skip to content
Screener

Kailera Therapeutics KLRA EPS (Diluted)

EPS (Diluted) at other companies

Veradermics logo
VeradermicsMANE
-$1.32+93.3%
BK
BKBK
$2.24+41.8%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
-$0.05+54.5%
Schering-Plough logo
Schering-PloughSGP
-$0.69+82.6%
Dycom Industries logo
Dycom IndustriesDY
$3.00+43.5%
Target logo
TargetTGT
$1.71-24.7%

Other financials

Income statement

See full
Operating income-$84.7M-314%
Net income-$78.9M-339%

Balance sheet

See full
Cash & equivalents$111.8M+9.9%
Total debt$10.5M—
Total equity-$432.1M-83.7%
Total assets$624.8M—

Cash flow

See full
Operating cash flow-$68.3M-275%

Valuation

See full
Market cap$2.44B-15.8%
Enterprise value$2.34B—

Returns & leverage

See full
Debt / equity-0×—
Current ratio9.7×—

Where this comes from

Reported directly by Kailera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026. Open the filing →

Filed
May 26, 2026, 4:29 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-239417

FAQ

What is Kailera Therapeutics's EPS (diluted)?
Kailera Therapeutics (KLRA) reported EPS (diluted) of -$3,650.00 in Q1 2026.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Kailera Therapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude